A urine biomarker for severe obstructive sleep apnoea patients: lipocalin-type prostaglandin D synthase

Chihara Yuichi, Chin Kazuo, Aritake Kosuke, Harada Yuka, Toyama Yoshiro, Murase Kimihiko, Yoshimura Chikara, Hitomi Takefumi, Oga Toru, Mishima Michiaki, Urade Yoshihiro

Source: Eur Respir J 2013; 42: 1563-1574
Journal Issue: December
Disease area: Sleep and breathing disorders

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chihara Yuichi, Chin Kazuo, Aritake Kosuke, Harada Yuka, Toyama Yoshiro, Murase Kimihiko, Yoshimura Chikara, Hitomi Takefumi, Oga Toru, Mishima Michiaki, Urade Yoshihiro. A urine biomarker for severe obstructive sleep apnoea patients: lipocalin-type prostaglandin D synthase. Eur Respir J 2013; 42: 1563-1574

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Urinary biomarkers for obstructive sleep apnea syndrome: Lipocalin type prostaglandin-D synthase and F2-isoprostane
Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality
Year: 2018

Oral nitric oxide in obstructive sleep apnoea (OSA)
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008


Decreased plasma levels of nitric oxide (NO) derivatives in obstructive sleep apnea (OSA): response to automatic positive airway pressure (APAP) therapy
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007

Increased alveolar nitric oxide by trumpet model in patients with obstructive sleep apnoea
Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health
Year: 2012


Diurnal variation of exhaled nitric oxide in obstructive sleep apnea syndrome and healthy subjects
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008


Exhaled nitric oxide is not altered in patients with obstructive sleep apnea syndrome
Source: Annual Congress 2007 - Airway regulation, provocation and monitoring II
Year: 2007


Nitric oxide in airways of patients with obstructive sleep apnea
Source: Eur Respir J 2005; 26: Suppl. 49, 356s
Year: 2005

Interrelationships between oxidative stress and MMP-9 in subjects with severe obstructive sleep apnea syndrome
Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea
Year: 2016


Exhaled nitric oxide in obstructive sleep apnea (OSA) patients: short and long term response to automatic positive airway pressure (APAP) therapy
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


Serum vitamin D levels in patients with obstructive sleep apnea syndrome and concentration changes after continuous positive airway pressure treatment
Source: Virtual Congress 2020 – Treatment of obstructive sleep apnoea and its effects
Year: 2020


Nitric oxide and obstructive sleep apnea syndrome (OSAS): reflection of inflammation and oxidative stress
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008


Vitamin D deficiency and excessive daytime sleepiness in obstructive sleep apnea: Is there a correlation?
Source: Annual Congress 2011 - Obstructive sleep apnoea: clinical aspects I
Year: 2011


Serum vitamin D levels are associated with markers of hypoxia in obstructive sleep apnea patients
Source: Annual Congress 2013 –Heart, blood and metabolism in sleep disordered breathing
Year: 2013

The role of vitamin D in obstructive sleep apnoea syndrome
Source: Breathe, 14 (3) 206; 10.1183/20734735.000618
Year: 2018



Concentration of exhaled nitric oxide (FENO) in patients with obstructive sleep apnea
Source: Eur Respir J 2004; 24: Suppl. 48, 118s
Year: 2004

Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2003; 22: Suppl. 45, 467s
Year: 2003

Effect of nasal CPAP on exhaled nitric oxide in patients with obstructive sleep apnea
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007

Fibrinogen level in patients with severe obstructive sleep apnoea syndrome (OSAS). Effect of n-CPAP therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 216s
Year: 2001

Hepcidin: the new marker for determining nocturnal hypoxia in patients with obstructive sleep apnea
Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing
Year: 2009


impact of continous positive airway pressure therapy on exhaled nitic oxide in obstructive sleep apnea syndrome
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019